COLL — COLLEGIUM PHARMACEUTICAL, INC

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1267565 ·
Last close
$25.55
Market Cap
$793.98M
52W High
$50.79
52W Low
$21.43
ADV30
640,177
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 216,339,000 125,418,000 25,827,000 21,759,000 2,095,936,000 144,797,000 1,799,500,000
Jun 2026 199,878,000 110,292,000 3,698,000 -15,051,000 2,135,790,000 129,467,000 1,823,881,000
Mar 2026 193,520,000 117,246,000 30,896,000 14,496,000 1,651,955,000 268,648,000 1,339,533,000
Dec 2025 205,449,000 128,378,000 60,738,000 16,963,000 1,656,834,000 231,252,000 1,355,159,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$338,020,000
Investing CF
$-521,310,000
Financing CF
$177,999,000
CapEx
$-1,732,000
Dividends Paid
—
Buybacks
$-50,000,000
EPS Diluted TTM
$1.00
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-79,925,000
Inventory
$88,202,000
Receivables
$310,785,000
ST Investments
$0
EBIT TTM
$118,766,000
Pretax Income TTM
$42,150,000
Interest Exp TTM
$76,616,000
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$815,185,984
EBITDA
$419,617,984
Free Cash Flow
$366,986,496
Enterprise Value
$1,815,156,992
Total Cash
$144,796,992
Total Debt
$1,207,618,048
Shares Out
31,075,424
Trailing EPS
$1.09
Book Value
$9.54
ROE
13.4%
ROA
6.3%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 780,567,000 178,454,000 62,870,000 1,656,834,000 1,355,159,000 301,675,000 329,323,000
Dec 2024 631,449,000 166,981,000 69,190,000 1,663,591,000 1,434,749,000 228,842,000 204,980,000
Dec 2023 566,767,000 166,961,000 48,155,000 1,143,308,000 947,877,000 195,431,000 274,749,000
Dec 2022 463,933,000 33,319,000 -25,002,000 1,174,131,000 979,289,000 194,842,000 124,230,000

TTM Snapshot

Revenues TTM
$808,208,000
NetIncome TTM
$47,915,000
OpCashFlow TTM
—
Assets (Latest)
$2,135,790,000
Forward EPS
$7.26

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $45.00 · spot: $25.93 · call volume: 24 · put volume: 418
Expected Move to 2026-12-18: ±$2.80 (10.80%) — implied range $23.13 – $28.73 · ATM straddle on $25.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
LXRX LEXICON PHARMACEUTICALS, INC. $792.52M $1.78 —
ARDX ARDELYX, INC. $799.36M $3.18 —
IRWD IRONWOOD PHARMACEUTICALS INC $806.23M $4.87 —
RIGL RIGEL PHARMACEUTICALS INC $808.18M $42.92 —
SNDX Syndax Pharmaceuticals Inc $828.26M $9.20 —

News headlines (Yahoo Finance, 1h cache)

Wall Street Analysts Believe Collegium Pharmaceutical (COLL) Could Rally 81.63%: Here's is How to Trade
2026-11-10 13:55 · Yahoo
COLL Q3 2026 deep dive: ADHD portfolio drives growth as pain business stabilizes
2026-11-10 10:37 · Yahoo
Collegium Pharmaceutical (COLL) Stock Gets Fair Value Trim As Analysts Weigh Pain And ADHD
2026-11-10 07:10 · Yahoo
Collegium Pharmaceutical Inc (COLL) (Q3 2026) Earnings Call Highlights: ADHD Franchise Hits ...
2026-11-06 21:09 · Yahoo
Collegium Pharmaceutical, Inc. Q3 2026 Earnings Call Summary
2026-11-05 23:28 · Yahoo
Collegium (COLL) Q3 2026 Earnings Call Transcript
2026-11-05 20:13 · Yahoo
Collegium Pharmaceutical Q3 Earnings Call Highlights
2026-11-05 15:14 · Yahoo
Collegium Pharmaceutical (COLL) Tops Q3 Earnings and Revenue Estimates
2026-11-05 13:35 · Yahoo
Collegium Pharmaceutical (NASDAQ:COLL) posts in line Q3 2026 sales and full year revenue guidance above estimates, stock soars
2026-11-05 13:33 · Yahoo
J&J to Boost Ophthalmology Pipeline With $2.2B Ollin Acquisition
2026-11-17 14:21 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.